News

Oxeia’s lead program, OXE-103, uniquely targets the metabolic injury and energy crisis underlying acute concussion pathology. OXE-103 restores mitochondrial homeostasis via a well-characterized mechanism of action and may

The strategic alliance combines the strength of Optum’s clinical data set derived from electronic health records (EHRs), claims data assets and analytics with PAREXEL’s global, site-based research experience.

The financing was co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor, UK based Fort Rock Capital. Existing investors Bayern Kapital and funds advised

AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells. These non-patient specific (allogeneic) AST-VAC2 cells are engineered to express a modified

TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential. The previous Phase 1b trial of TTP273 demonstrated robust effects on postprandial and fasting glucose. All doses

Acute radiation syndrome comprises serious bone marrow, gastrointestinal, and other toxicities arising from exposure to high doses of radiation. In order to qualify for orphan drug designation with

In a declaration signed by 85 companies and nine industry associations across 18 countries, they urged governments and industry to work in parallel in the development of new

The company is developing ALKS 5461, a once-daily, oral medicine to treat major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical

The agency approved Kyprolis in combination with dexamethasone or with lenalidomide plus dexamethasone to treat patients with relapsed or refractory multiple myeloma who have received one to three